High Vista Strategies LLC Sarepta Therapeutics, Inc. Transaction History

High Vista Strategies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $267,912 - $387,341	2,364 New	2,364 $373,000
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $22,960 - $27,684	-224 Reduced 4.48%	4,781 $579,000
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $288,131 - $425,670	-2,708 Reduced 35.11%	5,005 $573,000
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $29,854 - $39,110	-296 Reduced 3.7%	7,713 $999,000
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $119,016 - $187,445	-1,572 Reduced 16.41%	8,009 $885,000
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $108,391 - $152,912	-1,729 Reduced 15.29%	9,581 $718,000
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $714,226 - $1.02 Million	11,310 New	11,310 $884,000
Q1 2021 May 17, 2021	SELL	$72.25 - $168.95 $409,440 - $957,439	-5,667 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$125.56 - $178.74 $711,548 - $1.01 Million	5,667 New	5,667 $966,000
Q3 2020 Nov 16, 2020	SELL	$127.12 - $172.34 $326,698 - $442,913	-2,570 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $239,010 - $441,268	2,570 New	2,570 $412,000

525

84.4M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.96B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.